Question 1

Has Bun Siu received payments from drug or device companies?

Accepted Answer

Yes. Drug and device makers reported $13,357,705 in general payments to Bun Siu across 798 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Question 2

Does a payment mean Bun Siu did something wrong?

Accepted Answer

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Question 3

Where does this information about Bun Siu come from?

Accepted Answer

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Company	Payments	Total
AstraZeneca	7	$5,000,655
Astrazeneca UK Limited	3	$2,590,626
Pfizer	112	$2,272,258
AbbVie(2 entities)	151	$1,027,950
Organon	103	$497,736
Alnylam Pharmaceuticals Inc.	190	$381,295
Incyte Corporation	53	$307,262
Novartis	7	$286,803
Eli Lilly	2	$168,194
E.r. Squibb & Sons, L.L.C.	4	$151,194
Bavarian Nordic A/s	14	$142,303
Merck	4	$126,029
Mitsubishi Tanabe Pharma Development America, Inc.	8	$114,098
Acadia Pharmaceuticals Inc	10	$92,405
VYNE Pharmaceuticals Inc.	14	$68,914
Teva Pharmaceuticals USA, Inc.	20	$49,403
Dermavant Sciences, Inc.	69	$21,371
Grifols Shared Services North America, Inc.	4	$18,490
Tanabe Pharma America, Inc.	11	$14,068
GSK	4	$10,909
Bayer	1	$8,250
Genentech, Inc.	1	$5,000
Myovant Sciences Inc.	2	$2,119
Merz North America, Inc.	4	$374

Bun Siu

Payments from drug & device makers

Who reported the general payments